RETA GLP-3 — 30 mg

Retatrutide, also designated LY3437943, combines activity at three hormone receptors within one molecule: GIP, GLP-1, and glucagon. Umbrella lists it as retatrutide and includes GLP-3R among alternate product names. This labeling refers to the product’s triple-agonist positioning, not to a recognized GLP-3 receptor or a mixture of three separate drugs. Its development centers on coordinated control of appetite, glucose regulation, and energy metabolism.

The seller highlights a 2023 randomized phase 2 obesity trial. Investigators reported substantial weight reduction over 48 weeks, with the largest study-group mean approaching one quarter of starting body weight. Gastrointestinal events were prominent, and heart-rate changes were also monitored. Lilly’s accompanying announcement presents the molecule as a multi-hormone approach to obesity research. These descriptions explain the commercial emphasis on weight loss and metabolic effects, while remaining specific to the studied molecule and trial populations. A research-vial listing is a separate product context from the sponsor-manufactured clinical material, and the alternate GLP-3 name does not itself establish chemical identity or equivalence.